The RTS,S Cinical Trials Partnership. first results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. published online, 10.1056/nejmoa1102287 (18 October 2011).
Cohen, J., Nussenzweig, V., Nussenzweig, R., Vekemans, J. & Leach, A. From the circumsporozoite protein to the RTS, S vaccine. Hum. Vaccin. 6, 90–96 (2010).
Stewart, V.A. et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75, 2283–2290 (2007).
Bojang, K.A. et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358, 1927–1934 (2001).
Good, M.F. Our impasse in developing a malaria vaccine. Cell. Mol. Life Sci. 68, 1105–1113 (2011).
Barry, A.E., Schultz, L., Buckee, C.O. & Reeder, J.C. et al. Contrasting population structures of the genes encoding ten leading malaria vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. PLoS One 4, e8497 (2009).
Bejon, P. et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359, 2521–2532 (2008).
Asante, K.P. et al. Safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect. Dis. 11, 741–749 (2011).
Moorthy, V., Reed, Z. & Smith, P.G. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine 25, 5115–5123 (2007).
Alonso, P.L. et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366, 2012–2018 (2005).